U.S. markets closed

Deltron, Inc. (DTRO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.00300.0000 (0.00%)
At close: 9:30AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0030
Open0.0030
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0030 - 0.0030
52 Week Range0.0001 - 0.0045
Volume215
Avg. Volume1,721
Market Cap100,922
Beta (5Y Monthly)-0.46
PE Ratio (TTM)N/A
EPS (TTM)-7.2270
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI
    Business Wire

    Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI

    Gilead Sciences, Inc. (Nasdaq: GILD) today presented additional results from the Phase 2/3 CAPELLA trial evaluating the company’s investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, in heavily treatment-experienced people with multi-drug resistant HIV-1 infection. The data build on the positive primary endpoint results announced previously. The new interim efficacy results demonstrate that lenacapavir administered subcutaneously every six months maintained high rates of virologic suppression through 26 weeks in a difficult-to-treat patient population with limited therapy options and high unmet medical need. In this analysis of the ongoing maintenance period of CAPELLA, which evaluated lenacapavir in combination with an optimized background regimen, 73% (n=19/26) of participants who reached Week 26 since the first dose of subcutaneous lenacapavir achieved undetectable viral load (<50 copies/mL). The data were presented at the 28th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2021).

  • Yahoo Finance Video

    Fmr. White House Doctor: It’s ‘ill advised’ to relax COVID-19 mandates amid spreading variants

    Dr. Jennifer Pena, Nurx Chief Medical Officer & Former White House Medical Unit Physician for Obama, Biden and Pence, joins Yahoo Finance’s Julie Hyman and Alexis Christoforous to discuss the latest coronavirus updates and women in medicine.

  • Gilead’s Kite Receives FDA Approval For Yescarta Immunotherapy; Street Sees 17% Upside
    SmarterAnalyst

    Gilead’s Kite Receives FDA Approval For Yescarta Immunotherapy; Street Sees 17% Upside

    Kite, a unit of Gilead Sciences, announced that the US Food and Drug Administration (FDA) has approved its Yescarta T cell immunotherapy. The therapy is a first-of-its-kind treatment for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. The Gilead (GILD) company said that the US regulator’s decision was based on ZUMA-5, a single-arm, open-label study, that demonstrated 91% of patients with relapsed or refractory FL (n=81) responded to Yescarta. Shares of the biopharmaceutical company increased 2.2% to close at $64.62 on March 5. Kite CEO Christi Shaw said, “As we look to bring the hope of survival to more patients in need, today’s FDA decision represents a real step forward in our commitment in hematologic malignancies.” (See Gilead stock analysis on TipRanks) “Advancing CAR T therapies for patients across lymphomas remains a cornerstone of our cell therapy development program, and we are excited about the potential of Yescarta for patients with indolent follicular lymphoma,” Shaw added. On Feb. 10, Mizuho Securities analyst Salim Syed maintained a Buy rating and a price target of $81 (25.4% upside potential) on the stock after Galapagos and Gilead discontinued ISABELA Phase 3 clinical studies. The rest of the Street is cautiously optimistic about the stock with a Moderate Buy consensus rating. That’s based on 11 analysts suggesting a Buy, 9 analysts recommending a Hold and 1 analyst suggest a Sell. The average analyst price target of $75.73 implies 17.2% upside potential to current levels. Shares have increased 7.5% so far this year. Related News: Amgen Inks $1.9B Deal To Buy Five Prime Therapeutics; Shares Pop 79% Kroger Tops 4Q Profit Estimates As Online Sales Spike 118%; Shares Gain BlueLinx Posts Blowout Quarter; Stock Rises 9% More recent articles from Smarter Analyst: Chevron Inks Deal To Buy Noble Midstream Partners; Shares Gain 4% Abbott’s Alinity m Resp-4-Plex Test Cleared For Emergency Use In US; Street Says Buy Eli Lilly Wins EMA Nod For COVID-19 Antibody Therapy; Shares Jump 3% GE To Combine GECAS Business With AerCap – Report